Bovie Medical Corp.

Bovie Medical Receives 510K Clearance for Its Cool-Coagâ„¢ Generator and Open Handpiece

Bovie Medical (NYSE:BVX) announced today that it has received 510K clearance from the FDA for a new J-Plasma® generator and handpiece that incorporate Cool-Coag™ technology.

Cool-Coag™ is a new technology that combines the unique benefits of J-Plasma®, namely increased precision with minimal thermal spread, with standard monopolar coagulation and helium spray coagulation capabilities, all in one handpiece. This allows the surgeon to benefit from using a single device that offers the greater control of tissue effect that J-Plasma® delivers, while being able to switch to a monopolar or helium spray coagulation mode with just the push of a button.

“The development of Bovie’s Cool-Coag™ technology is a direct result of feedback from surgeons who have used our J-Plasma® product for procedures that require greater coagulation capability, specifically in the areas of gynecologic oncology and surgical oncology,” said Robert L. Gershon, Chief Executive Officer. “The unique flexibility of Cool-Coag™ enables the surgeon to use J-Plasma® to perform the most delicate procedures, where precision and low risk of injury to surrounding tissue are paramount and also have the full power of monopolar coagulation to control, pinpoint and diffuse bleeding as needed.”

“This new Cool-Coag™ technology has the potential to increase usage of the J-Plasma® device in many of our most complex cancer procedures. It combines J-Plasma®’s ability to be used close to vital structures with minimal collateral damage and standard full monopolar coagulation capability, all in one hand-held instrument. Cool-Coag™ may also expand the use of J-Plasma® in additional procedures and specialties,” said Dr. Dennis Chi, head of the Ovarian Cancer Surgery at Memorial Sloan Kettering Cancer Center in New York City.

“We are pleased with our ability to continue to provide innovation that meets the needs of surgeons and are confident in the substantial growth opportunity for J-Plasma® as we continue to penetrate the market,” Mr. Gershon noted.

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s www.boviemed.com.

EN
27/03/2017

Reports on Bovie Medical Corp.

 PRESS RELEASE

Bovie Medical Corporation to Present at the Wedbush PacGrow Healthcare...

CLEARWATER, Fla.--(BUSINESS WIRE)-- Bovie Medical Corporation (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that management will participate in the Wedbush PacGrow Healthcare Conference at the Le Parker Meridien Hotel in New York, New York. Management will host a presentation with investors on Tuesday, August 15 at 3:05 p.m. Eastern Time. A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Bovie Me...

 PRESS RELEASE

Bovie Medical Corporation Reports Second Quarter 2017 Financial Result...

CLEARWATER, Fla.--(BUSINESS WIRE)-- Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today reported financial results for its second fiscal quarter ended June 30, 2017. Second Quarter 2017 Financial Summary: Total Q2 revenue of $9.8 million, up 5.4% year-over-year. Advanced Energy revenue increased 137% year-over-year to $1.8 million, driven by strong J-Plasma® sale...

 PRESS RELEASE

Bovie Medical Corporation to Release Second Quarter 2017 Financial Res...

CLEARWATER, Fla.--(BUSINESS WIRE)-- Bovie Medical (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the second quarter of 2017 will be released after the market closes on Wednesday, August 2. Management will host a conference call at 4:30 p.m. Eastern Time on August 2 to discuss the results of the quarter and host a question and answer session. To listen to the call by phone, interested parties may dial 844-507-6493 (or 64...

 PRESS RELEASE

Bovie Medical Corporation to Present at the JMP Securities Life Scienc...

CLEARWATER, Fla.--(BUSINESS WIRE)-- Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that management will participate in the JMP Securities Life Sciences Conference at the St. Regis Hotel in New York, New York. Management will host a presentation with investors on Wednesday, June 21 at 12:00 p.m. Eastern Time. A live audio webcast of the presentation will be provided under the ‘Company Events’ secti...

 PRESS RELEASE

Bovie Medical Corporation Reports First Quarter 2017 Financial Results...

CLEARWATER, Fla.--(BUSINESS WIRE)-- Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today reported financial results for its first fiscal quarter ended March 31, 2017. First Quarter 2017 Financial Summary: Total Q1 revenue of $8.4 million, up 7.9% year-over-year. Domestic Q1 revenue of $7.0 million, up 5.7% year-over-year. International Q1 revenue of $1.4 million, up...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch